Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYCNYSE:CYBNNASDAQ:IMTXNASDAQ:KROS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$9.30+2.4%$8.71$6.10▼$28.67$643.58M1.6396,144 shs192,612 shsCYBNCybin$6.50-1.8%$6.93$4.81▼$14.44$142.18M0.59239,352 shs172,842 shsIMTXImmatics$5.23+4.4%$4.46$3.30▼$13.77$635.71M0.85655,477 shs698,994 shsKROSKeros Therapeutics$14.65+0.5%$11.92$9.12▼$72.37$594.95M1.39811,465 shs651,753 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics+2.42%+10.45%+15.53%-30.55%-61.57%CYBNCybin-1.81%-7.01%+3.83%-34.41%+1,757.14%IMTXImmatics+4.39%+15.71%+25.42%-4.39%-51.62%KROSKeros Therapeutics+0.55%+3.10%+45.92%+28.51%-74.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCYCBicycle Therapeutics3.5924 of 5 stars4.44.00.00.02.02.50.6CYBNCybin2.2002 of 5 stars3.50.00.00.02.00.81.3IMTXImmatics1.9536 of 5 stars3.61.00.00.03.21.70.0KROSKeros Therapeutics3.1546 of 5 stars3.32.00.00.04.25.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.78Moderate Buy$26.00179.57% UpsideCYBNCybin 3.00Buy$86.001,223.08% UpsideIMTXImmatics 3.20Buy$16.67218.67% UpsideKROSKeros Therapeutics 2.57Moderate Buy$40.33175.31% UpsideCurrent Analyst Ratings BreakdownLatest CYBN, BCYC, IMTX, and KROS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025BCYCBicycle TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $32.005/2/2025BCYCBicycle TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$17.00 ➝ $14.005/2/2025BCYCBicycle TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$26.00 ➝ $22.005/2/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.005/1/2025BCYCBicycle TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $15.004/9/2025BCYCBicycle TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/9/2025KROSKeros TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$43.00 ➝ $25.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/1/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.00 ➝ $15.004/1/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$25.72M25.02N/AN/A$12.35 per share0.75CYBNCybinN/AN/AN/AN/A$10.83 per shareN/AIMTXImmatics$155.84M4.08N/AN/A$2.88 per share1.82KROSKeros Therapeutics$3.55M167.59N/AN/A$11.09 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$180.66M-$3.14N/AN/AN/A-450.64%-27.35%-20.81%N/ACYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/AIMTXImmatics-$104.98M$0.14N/AN/AN/A-47.94%-15.90%-9.38%5/13/2025 (Estimated)KROSKeros Therapeutics-$152.99M-$5.01N/AN/AN/A-27,890.94%-41.74%-38.42%5/6/2025 (Estimated)Latest CYBN, BCYC, IMTX, and KROS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025KROSKeros Therapeutics$0.1614N/AN/AN/A$62.01 millionN/A5/13/2025Q1 2025IMTXImmatics-$0.39N/AN/AN/A$14.92 millionN/A5/1/2025Q1 2025BCYCBicycle Therapeutics-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million2/26/2025Q4 2024KROSKeros Therapeutics-$1.36-$1.14+$0.22-$1.14$37.32 million$3.04 million2/25/2025Q4 2024BCYCBicycle Therapeutics-$0.85-$0.75+$0.10-$0.75$5.47 million$3.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A17.1317.13CYBNCybinN/A24.2424.24IMTXImmaticsN/A3.983.98KROSKeros TherapeuticsN/A19.0319.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%CYBNCybin17.94%IMTXImmatics64.41%KROSKeros Therapeutics71.56%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%CYBNCybin15.00%IMTXImmatics3.30%KROSKeros Therapeutics22.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.20 million63.18 millionOptionableCYBNCybin5021.48 million17.96 millionNot OptionableIMTXImmatics260121.55 million115.42 millionOptionableKROSKeros Therapeutics10040.61 million31.23 millionOptionableCYBN, BCYC, IMTX, and KROS HeadlinesRecent News About These CompaniesImplied Volatility Surging for Keros Therapeutics Stock OptionsMay 2 at 12:16 PM | theglobeandmail.comTCG Crossover Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)May 1 at 8:03 AM | marketbeat.comDarwin Global Management Ltd. Has $26.71 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)May 1 at 8:03 AM | marketbeat.comEmerald Mutual Fund Advisers Trust Acquires 42,734 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)May 1 at 7:19 AM | marketbeat.comLynx1 Capital Management LP Buys New Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)April 29, 2025 | marketbeat.comNebula Research & Development LLC Increases Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)April 29, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Stock Holdings Boosted by Blue Owl Capital Holdings LPApril 26, 2025 | marketbeat.comRussell Investments Group Ltd. Trims Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)April 26, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives $40.33 Average PT from BrokeragesApril 25, 2025 | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Moderate Buy" by AnalystsApril 24, 2025 | marketbeat.comGeode Capital Management LLC Raises Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)April 23, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 182,314 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)April 23, 2025 | marketbeat.comAltium Capital Management LLC Has $2.77 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)April 20, 2025 | marketbeat.comWalleye Capital LLC Makes New Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)April 20, 2025 | marketbeat.comAlliancebernstein L.P. Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)April 19, 2025 | marketbeat.comInsider Buying: Keros Therapeutics, Inc. (NASDAQ:KROS) Major Shareholder Purchases 934,258 Shares of StockApril 16, 2025 | marketbeat.comVanguard Group Inc. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS)April 16, 2025 | marketbeat.comAdar1 Capital Management, Llc Acquires 934,258 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) StockApril 15, 2025 | insidertrades.comFederated Hermes Inc. Purchases New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)April 15, 2025 | marketbeat.comNorges Bank Invests $1.03 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)April 14, 2025 | marketbeat.comKeros Therapeutics Target of Unusually Large Options Trading (NASDAQ:KROS)April 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, BCYC, IMTX, and KROS Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$9.30 +0.22 (+2.42%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$9.16 -0.14 (-1.45%) As of 05/2/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Cybin NYSE:CYBN$6.50 -0.12 (-1.81%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$6.48 -0.01 (-0.23%) As of 05/2/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Immatics NASDAQ:IMTX$5.23 +0.22 (+4.39%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$5.24 +0.00 (+0.10%) As of 05/2/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Keros Therapeutics NASDAQ:KROS$14.65 +0.08 (+0.55%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$14.49 -0.16 (-1.09%) As of 05/2/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
